Success Story: Cancer-Focused Medicinal Chemistry Research Secures NIW Approval
Client’s Testimonial:
"Thank you very much for your time and efforts in my case!"
On May 20th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Associate in the Field of Medicinal Chemistry (Approval Notice).
General Field: Medicinal Chemistry
Position at the Time of Case Filing: Postdoctoral Associate
Country of Origin: China
State of Residence at the Time of Filing: Texas
Approval Notice Date: May 20th, 2026
Processing Time: 22 months, 1 day
Case Summary:
Our firm recently secured an NIW petition for a postdoctoral associate from China whose work centers on medicinal chemistry. The client holds a Ph.D. in medicinal chemistry and has developed expertise in drug target identification, ligand discovery, structural optimization, and anticancer therapeutic design.
The case centered on his proposed endeavor, which focused on identifying therapeutic compounds for novel disease targets to support more effective and less toxic medical treatments. Our legal team framed this work around a broader public health need: improving targeted therapies, reducing treatment side effects, and supporting U.S. leadership in biotechnology and pharmaceutical innovation.
The petition highlighted a strong research record, including 8 peer-reviewed journal articles, 6 of them first-authored, along with 1 patent application and 2 granted patents. His work had received 70 citations, and one of his papers ranked among the top 20% of most-cited Pharmacology & Toxicology articles for its publication year. We also emphasized the client’s extensive peer-review service. He had completed at least 140 reviews for journals in related fields, demonstrating that editors repeatedly relied on his expertise to evaluate the work of other researchers. The case further documented how independent researchers used his findings in studies involving organoselenium compounds, immune checkpoint inhibitors, and natural-product-based therapeutic development.
Additional evidence showed that his research had received funding support from the National Natural Science Foundation of China, reflecting broader recognition of the value of his work. Together, these materials showed that the client was well-positioned to continue advancing research with meaningful implications for cancer treatment and medicinal chemistry.
This outcome reflects NAILG’s careful presentation of a petition that connected the client’s medicinal chemistry background, patent record, peer review activity, citation impact, and future research plans to broader U.S. interests in targeted cancer therapy, drug discovery, and public health innovation.